RE: Media / Social Media19 Apr 2020 20:43
'Professor Tom Wilkinson, leading international lung disease specialist and Chief Investigator for the SG015 study, commented: "Respiratory virus infections, such as the common cold and flu, are a major cause of exacerbations of COPD, which are the second most common cause of unplanned hospital admission in England, so there is a real need for a treatment that helps patients when they have a cold or flu infection. The biomarker data from Part 1 indicate that we are 'switching on' antiviral defences in the lungs which we hope will translate into a clinical benefit in Part 2 of the study, when patients take either placebo or inhaled IFN-beta for 14 days when they have a confirmed respiratory viral infection. The trial is progressing well, and we are on track to complete the study during this coming winter virus season."'
He clearly refers to the need for a treatment...switching on the anti viral response is a treatment...